| Term 
 
        | Examples of Alkylating Agents |  | Definition 
 
        | 
CyclophosphamideMelphalanBusulfan |  | 
        |  | 
        
        | Term 
 
        | Mechanism of Action of Alkylating Agents |  | Definition 
 
        | Interfere with DNA synthesis by cross-linking DNA strands --> strand breaks; inhibit DNA replication/repair |  | 
        |  | 
        
        | Term 
 
        | Side Effects of Cyclophosphamide |  | Definition 
 
        | 
Haemorrhagic cystitisBladder TCC |  | 
        |  | 
        
        | Term 
 
        | Side Effects of All Alkylating Agents |  | Definition 
 
        | 
InfertilityMyelosuppressionTeratogenic (never in pregnancy unless the life of the mother is at stake)Secondary malignancy (AML, lymphoma) |  | 
        |  | 
        
        | Term 
 
        | What class of anti-neoplastic agents confers risk of secondary malignancy? |  | Definition 
 
        | Alkylating agents (AML, lymphoma) |  | 
        |  | 
        
        | Term 
 
        | Indications for Cyclophosphamide |  | Definition 
 
        | 
Haematological malignancies |  | 
        |  | 
        
        | Term 
 
        | Examples of platinum-based chemotherapeutics |  | Definition 
 
        | 
CisplatinCarboplatinOxaliplatin |  | 
        |  | 
        
        | Term 
 
        | Mechanism of action of platinum-based chemotherapeutics |  | Definition 
 
        | Causes cross-links of DNA |  | 
        |  | 
        
        | Term 
 
        | Side effects common to all platinum-based chemotherapeutics |  | Definition 
 
        | 
InfertilityHypomagnesaemiaPeripheral neuropathy with cumulative dosing |  | 
        |  | 
        
        | Term 
 
        | Side effects of cisplatin |  | Definition 
 
        | 
Severe nausea & vomitingOtotoxicityNephrotoxicity |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | Mechanism of action of Taxanes |  | Definition 
 
        | Prevents microtubule formation by binding to tubulin dimers (M phase of cell cycle) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 
Peripheral neuropathyFluid retentionNeutropaeniaInfertility, amenorrhoeaHypersensitivity reactionNeed to dose reduce in liver impairment |  | 
        |  | 
        
        | Term 
 
        | Mechanism of Action of, and indications for Tamoxifen |  | Definition 
 
        | ER+ competitive antagonism ER+ Breast Ca (pre- and post-menopausal) |  | 
        |  | 
        
        | Term 
 
        | Mechanism of action of, and indications for, Aromatase Inhibitors |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Side effects of Tamoxifen |  | Definition 
 
        | 
Hot flushesLow libidoDVT (2-3x risk)Endometrial cancer (2-3x risk) |  | 
        |  | 
        
        | Term 
 
        | Side effects of Aromatase Inhibitors |  | Definition 
 
        | 
Hot flushesLow libidoArthralgiasOsteopaenia |  | 
        |  | 
        
        | Term 
 
        | Examples of ALK-Inhibitors |  | Definition 
 
        | 
Alectinib (2nd gen, new standard of care, brain penetration)Crizotinib (1st gen, lots of side effects)Others: Ceritinib, lorlatinib (brain penetration) |  | 
        |  | 
        
        | Term 
 
        | What is the function of ALK? |  | Definition 
 
        | Transmembrane tyrosin kinase receptor Activates a whole bunch of pathways (JAK, STAT, mTOR, sonic hedgehog & more) to stimulate cell growth, transformation, and anti-apoptotic signalling |  | 
        |  | 
        
        | Term 
 
        | What malignancies are ALK-Inhibitors used for? |  | Definition 
 
        | NSCLC (5% of adenocarcinomas are ALK+, typically younger patients, non-smokers) |  | 
        |  | 
        
        | Term 
 
        | Side effects of ALK-Inhibitors |  | Definition 
 
        | First generation (crizotinib) is the worst 
Nausea, vomiting, diarrhoea (mild)Hepatitis (severe, rare)Pneumonitis (severe, rare)Visual phenomenaLow testosterone (universal)Bradycardia |  | 
        |  | 
        
        | Term 
 
        | What are some examples of intracellular EGFR inhibitors? |  | Definition 
 
        | 
Erlotinib, gefitinib (1st gen)Afatinib (2nd gen)Osimertinib (3rd gen) |  | 
        |  | 
        
        | Term 
 
        | Side effects of EGFR inhibitors |  | Definition 
 
        | Acneform rash = means that it's working! Diarrhoea Hepatitis, pneumonitis (rare) |  | 
        |  | 
        
        | Term 
 
        | Why would you use Osimertinib rather than an earlier generation EGFR inhibitor? |  | Definition 
 
        | Overcomes resistance to earlier generation EGFR inhibitors 
50% of patients develop T790M mutation - change to structure of binding pocket meaning older EGFR-i's can't bindOsimertinib overcomes this |  | 
        |  | 
        
        | Term 
 
        | What is the mechanism of action of Imatinib? |  | Definition 
 
        | Multi-kinase inhibitor, including BCR-Abl and cKIT |  | 
        |  | 
        
        | Term 
 
        | What are some other multi-kinase inhibitors similar to Imatinib? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Mechanism of Action of Durvalumab |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Indications for Durvalumab |  | Definition 
 
        | 
Stage 3 Lung Ca - Neoadjuvant (PACIFIC trial) |  | 
        |  | 
        
        | Term 
 
        | Mechanism of action of Capecitabine |  | Definition 
 
        | Anti-metabolite (pyrimidine analogue) Plantar-palmar erythema |  | 
        |  | 
        
        | Term 
 
        | What are some examples of extracellular EGFR inhibitors? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Side effects of VEGF inhibitors |  | Definition 
 
        | 
Hypertension - means that it's working!Proteinuria/nephrotic syndromeBleeding/increased risk of haemorrhageDelayed wound healing |  | 
        |  |